Valuation: Recursion Pharmaceuticals, Inc.

Market Cap 1.88B 1.61B 1.5B 1.38B 2.58B 180B 2.62B 17.77B 6.93B 90.21B 7.05B 6.89B 298B P/E 2026 *
-3.99x
P/E 2027 * -4.07x
Enterprise Value 1.49B 1.28B 1.19B 1.09B 2.05B 143B 2.08B 14.1B 5.5B 71.59B 5.59B 5.47B 237B EV / Sales 2026 *
34.9x
EV / Sales 2027 * 29.3x
Free-Float
97.72%
Yield 2026 *
-
Yield 2027 * -
1 day+4.79%
1 week+10.76%
Current month+16.67%
1 month+13.64%
3 months+12.54%
6 months+2.34%
Current year-14.43%
1 week 2.92
Extreme 2.92
3.63
1 month 2.86
Extreme 2.86
3.63
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
7.18
3 years 2.77
Extreme 2.77
15.74
5 years 2.77
Extreme 2.77
29.4
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 2025-12-31
Director of Finance/CFO 48 2024-11-19
Chief Tech/Sci/R&D Officer 57 2026-04-05
Director TitleAgeSince
Director/Board Member 44 2013-11-03
Director/Board Member 62 2013-11-03
Director/Board Member 37 2016-08-31
Date Insider Type Main position Quantity % Market Cap.
8/17/26 Tax

Chief Technology Officer

-26,657 0.0051%
8/17/26 Tax

Chief Executive Officer

-80,498 0.0153%
8/17/26 Tax

Chief Financial Officer

-25,018 0.0048%
Change 5-day change 1-year change 3-year change Capi.($)
+4.79%+10.76%-26.78%-60.41% 1.88B
-3.00%+2.27%+77.60%+109.33% 72.12B
+1.90%+23.53%+56.60%+97.76% 65.85B
+5.12%+25.22%+5.24%-0.82% 29.28B
+0.55%+1.64%-5.15%+471.68% 27.47B
+2.74%+12.98%+62.84%+28.14% 26.7B
+0.47%+6.12%+36.66%-13.79% 20.06B
+1.82%-6.67%+247.46%+393.10% 18.22B
+0.94%+3.36%+18.55%+532.94% 16.4B
+0.73%+5.54%+39.71%+153.07% 13.4B
Average +1.61%+8.60%+51.27%+171.10% 29.14B
Weighted average by Cap. +0.77%+9.49%+58.49%+156.40%

Financials

2026 *2027 *
Net sales 42.68M 36.56M 34.21M 31.32M 58.77M 4.08B 59.55M 404M 158M 2.05B 160M 157M 6.79B 56.25M 48.18M 45.08M 41.27M 77.45M 5.38B 78.48M 533M 208M 2.7B 211M 207M 8.94B
Net income -459M -393M -368M -337M -632M -43.89B -640M -4.34B -1.69B -22.05B -1.72B -1.69B -72.93B -474M -406M -380M -348M -653M -45.39B -662M -4.49B -1.75B -22.8B -1.78B -1.74B -75.41B
Net Debt -388M -332M -311M -284M -534M -37.08B -541M -3.67B -1.43B -18.63B -1.46B -1.42B -61.6B -227M -194M -182M -166M -312M -21.69B -316M -2.15B -837M -10.9B -851M -833M -36.04B
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
26-08-21 US$3.500 +4.79% 22,898,467
26-08-20 US$3.340 -4.57% 21,453,650
26-08-19 US$3.500 +13.27% 30,369,727
26-08-18 US$3.090 -0.64% 16,348,347
26-08-17 US$3.110 -1.58% 10,621,604
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
3.500USD
Average target price
7.217USD
Spread / Average Target
+106.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RXRX Stock